関連する実験動画

Updated: Jun 12, 2026

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
08:16

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Published on: June 17, 2015

アルツハイマー病におけるアミロイドベータ集積と神経炎症を標的とする:進歩と将来の方向性

Ioanna Dagla1, Faidon Gkikas1, Evagelos Gikas2

  • 1Bioanalytical Laboratory, GAIA Research Center, The National Natural History Museum Goulandris, 145 62, Athens, Greece.

Cells
|February 12, 2026
PubMed
まとめ

天然化合物は,アミロイドβ (Aβ) アグリゲーションと神経炎症を標的として,アルツハイマー病 (AD) に対して有望を示しています. ナノテクノロジーは,潜在的に疾患を改変する治療法の限界を克服して,その提供を強化します.

キーワード:
アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,アルツハイマー病 (Alzheimer's disease) とは,クロカス・サティブス L.EGCG EGCG EGCG EGCG EGCG EGCG EGCG EGCG EGCG EGCGアミロイド-β アグレゲーションカンナビジオール (Cannabidiol) とはカルキュミンはカルキュミンです.炎症性炎症症は,炎症性炎症と呼ばれるものです.ナノ医療 ナノ医療ナノ粒子 ナノ粒子天然製品 自然製品です.神経炎症による神経炎症です.レスベラトロール (Resveratrol) とは

さらに関連する動画

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

関連する概念動画

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...